A clinical trial investigating the combination of a PI3K inhibitor with a first-generation EGFR tyrosine kinase inhibitor (TKi) revealed antitumor activity but also late toxicity, as seen with gefitinib and buparlisib in NSCLC (NCT01570296)42. This evidence concerns the gene EGFR and non-small cell lung carcinoma.